Poland - Pharmaceutical products

Description

Adalimumab 40 mg - a detailed description of the subject of the contract is attached as Appendix 1 Golimumab 50 mg - a detailed description of the subject of the contract is attached as Appendix 1 Rituxymab 500 mg - a detailed description of the subject of the contract is attached as Appendix 1 Tocilizumab 400 mg, 200 mg; Tocilizumab 162 mg - a detailed description of the subject of the contract was placed in Appendix 1 Inflixymab 100 mg - a detailed description of the subject of the contract was placed in Appendix 1 Etanercept 50 mg - a detailed description of the subject of the contract was placed in Appendix 1 Ranibizumab 10 mg/1 ml - a detailed description of the subject of the contract was placed in Appendix 1 Ranibizumab 10 mg/1 ml - a detailed description of the subject of the contract was placed in Appendix 1 Etanercept 50 mg - a detailed description of the subject of the contract was placed in Appendix 1 Ranibizumab 10 mg/1 ml - a detailed description of the subject of the contract was placed in Appendix 1. a detailed description of the subject of the contract is attached as Appendix 1 Sekukinumab 150 mg - a detailed description of the subject of the contract is attached as Appendix 1 Argipressin 40 jm/2 ml - a detailed description of the subject of the contract is attached as Appendix 1 Vedolizumab 300 mg - a detailed description of the subject of the contract is attached as Appendix 1 Empaglyzine 10 mg, Baclofen 10 mg, Thephyllinum 300 mg - a detailed description of the subject matter of the order is presented in Attachment No. 1.

Opportunity closing date

17 June 2019

Value of contract

to be confirmed